|
Thalia Therapeutics PLC - biotechnology company developing innovative RNA therapeutics - Pretax loss is flat at £1.2 million in 2025 when compared to the year prior. Loss per share is 0.17 pence versus 0.31p the year before, revenue is little changed at £7,264 versus £7,282. Research and development costs fall to £214,120 from £390,387 and general and administration costs rise to £1.0 million from £837,996. ‘Alongside our internally developed assets, we are in advanced stages of potentially adding a clinical-stage microRNA therapeutic asset to the company’s portfolio. If successful, this, combined with the continued advancement of Nuvec, our dual-targeting siRNA programme, is the first step in creating a differentiated and valuable RNA therapeutics company,’ says Chief Executive David Solomon. Current stock price: 0.55 pence 12-month change: up 45% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
